Intravenous iron in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 15, Issue 37, 2009, Pages 4666-4674

  Muñoz, Manuel ^a   Gómez Ramírez, Susana ^b   García Erce, José Antonio ^c  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Anemia; Erythropoiesis stimulating agents; Functional iron deficiency; Inflammatory bowel disease; Intravenous iron; Iron deficiency; Oral iron

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS ION; FERROUS SULFATE; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FERRIC ION; FERRIC OXIDE, SACCHARATED; GLUCONIC ACID; MALTOSE;

ABDOMINAL PAIN; ABNORMAL FECES; ALGORITHM; ANAPHYLAXIS; ANEMIA; BIOLOGICAL ACTIVITY; BLACK STOOL; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ACCUMULATION; DRUG BINDING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ENTERITIS; EPIGASTRIC PAIN; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; INFECTION RISK; INJECTION SITE PAIN; INJECTION SITE REACTION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; LUNG EDEMA; MAXIMUM TOLERATED DOSE; METALLIC TASTE; NAUSEA; OXIDATIVE STRESS; PATIENT COMPLIANCE; PHLEBITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; THROMBOSIS; UNSPECIFIED SIDE EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

FERRIC COMPOUNDS; GLUCONATES; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; IRON; IRON-DEXTRAN COMPLEX; MALTOSE; TREATMENT OUTCOME;

EID: 70349782648     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4666     Document Type: Review

References (43)

1. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1299-1307 (Pubitemid 351678000)
2. Crichton RR, Danielsson BG, Geisser P. Iron therapy with special emphasis on intravenous administration. 4th ed. Bremen: UNI-Med Verlag AG, 2008
3. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18: 319-332
4. Andrews NC. Forging a field: the golden age of iron biology. Blood 2008; 112: 219-230
5. Beris P, Muñoz M, García-Erce JA, Thomas D, Maniatis A, Van der Linden P. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008; 100: 599-604 (Pubitemid 351774360)
6. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823-833
7. Maniatis A. The role of iron in anaemia management: can intravenous iron contribute to blood conservation? ISBT Sci Ser 2008; 3: 139-143
8. Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004; 15 Suppl 2: S99-S106
9. Van Wyck DB. Labile iron: manifestations and clinical implications. J Am Soc Nephrol 2004; 15 Suppl 2: S107-S111 (Pubitemid 39578824)
10. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004; 76: 74-78
11. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13: 381-384
12. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15 Suppl 2: S93-S98 (Pubitemid 39578822)
13. Macdougall IC. Experience with intravenous iron in nephrology. Semin Hematol 2006; 43: S9-S12
14. Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100: 2503-2509 (Pubitemid 43919683)
15. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-382 (Pubitemid 43159991)
16. Grau PW. Intravenous iron therapy. In: Beaumont C, Beris P, Beuzard Y, Brugnara C, editors. Disorders of iron homeostasis, erythrocytes, erythropoiesis. Paris: European School of Haematology, 2006: 420-434
17. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369: 1502-1504 (Pubitemid 46670290)
18. Beshara S, Sörensen J, Lubberink M, Tolmachev V, Långström B, Antoni G, Danielson BG, Lundqvist H. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003; 120: 853-859 (Pubitemid 36315111)
19. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009; 69: 739-756
20. Food and Drugs Administration Center for Drug Evaluation and Research. Summary minutes of the Drug Safety and Risk Management Advisory Committee. February 1, 2008 [online]. Available from: URL: http://www.fda.gov/ohrms/ dockets/ac/08/minutes/2008-4337m1-Final.pdf
21. Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion 2008; 48: 988-1000 (Pubitemid 351614910)
22. Muñoz M, Breymann C, García-Erce JA, Gómez- Ramírez S, Comin J, Bisbe E. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 2008; 94: 172-183
23. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19: 372-379 (Pubitemid 351240658)
24. Henry DH, Dahl NV, Auerbach M. Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis [Abstract] Blood 2007; 110: 1625
25. Vijverman A, Piront P, Belaiche J, Louis E. Evolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003. Acta Gastroenterol Belg 2006; 69: 1-4
26. Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, Gomollon F, Hjortswang H, Koutroubakis I, Kulnigg S, Oldenburg B, Rampton D, Schroeder O, Stein J, Travis S, Van Assche G. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545-1553
27. de la Morena F, Gisbert JP. [Anemia and inflammatory bowel disease] Rev Esp Enferm Dig 2008; 100: 285-293
28. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973; 26: 770-772
29. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, Berge RK, Hausken T. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058-1065 (Pubitemid 41291355)
30. de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 2005; 22: 1097-1105 (Pubitemid 41779517)
31. Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C, Petritsch W. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001; 96: 2382-2387 (Pubitemid 32769199)
32. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004; 39: 454-458 (Pubitemid 38626625)
33. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Granno C, Ung KA, Hjortswang H, Lindgren A, Unge P. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 1-8
34. Gisbert JP, Bermejo F, Pajares R, Pérez-Calle JL, Rodríguez M, Algaba A, Mancenido N, de la Morena F, Carneros JA, McNicholl AG, González-Lama Y, Maté J. Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15: 1485-1491
35. García-López S, Gomollón F, García-Erce JA, Araméndiz R, Sicilia B, Vicente R. Intravenous iron sucrose: a simple, safe, and quick method to treat anemia secondary to digestive diseases [Abstract]. Gastroenterology 2006; 130: A84
36. Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34: 286-290 (Pubitemid 34437521)
37. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-1192 (Pubitemid 351677967)
38. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE, Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C, McClelland DB, Norfolk DR, Soldan K, Taylor C, Revill J, Williamson LM, Cohen H. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20: 273-282 (Pubitemid 44428107)
39. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 2002; 32 Suppl 1: 70-78
40. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl 1999; 69: S71-S78
41. García-Erce JA, Cuenca J, Gómez-Ramírez S, Villar I, Herrera A, Muñoz M. [Therapeutic options for anemia management in orthopedic surgery]. Anemia 2009; 2: 17-27
42. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003; 533: 153-171 (Pubitemid 37487866)
43. Gasche C, Kulnigg S. Intravenous iron in inflammatory bowel disease. Semin Hematol 2006; 43: S18-S22 (Pubitemid 44486329)